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Abstract The term “gray-zone” lymphoma has been used
to denote a group of lymphomas with overlapping his-
tological, biological, and clinical features between various
types of lymphomas. It has been used in the context of
Hodgkin lymphomas (HL) and non-Hodgkin lymphomas
(NHL), including classical HL (CHL), and primary medi-
astinal large B cell lymphoma, cases with overlapping fea-
tures between nodular lymphocyte predominant Hodgkin
lymphoma and T-cell/histiocyte-rich large B cell lympho-
ma, CHL, and Epstein–Barr-virus-positive lymphoprolifer-
ative disorders, and peripheral T cell lymphomas simulating
CHL. A second group of gray-zone lymphomas includes B
cell NHL with intermediate features between diffuse large
B cell lymphoma and classical Burkitt lymphoma. In order
to review controversial issues in gray-zone lymphomas, a
joint Workshop of the European Association for Hemato-
pathology and the Society for Hematopathology was held
in Bordeaux, France, in September 2008. The panel
members reviewed and discussed 145 submitted cases and
reached consensus diagnoses. This Workshop summary is
focused on the most controversial aspects of gray-zone
lymphomas and describes the panel’s proposals regarding
diagnostic criteria, terminology, and new prognostic and
diagnostic parameters.
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With application of modern immunophenotypic and molec-
ular genetic techniques, most cases of lymphomas can be
successfully diagnosed and classified as one of the
currently recognized distinct disease entities. However,
there are some cases which show overlapping or borderline
morphological, biological, and clinical features between
various types of lymphomas. The 2008 World Health
Organization (WHO) classification of tumors of hemato-
poietic and lymphoid tissues [1] recognized this problem
and introduced two new provisional categories of B cell
lymphoma, unclassifiable, one with features intermediate
between diffuse large B cell lymphoma (DLBCL) and
Burkitt lymphoma (BL) [2] and the second with features
intermediate between DLBCL and classical Hodgkin
lymphoma (CHL) [3].
The first provisional category relates to the distinction of
classical BL from DLBCL with morphology similar to BL
and/or presence of an MYC translocation, with or without
other translocations. Many of these cases occur in adults
and morphologically resemble BL. Some of them were
previously classified as “Burkitt-like” lymphoma, a term
that has been deliberately abandoned [4]. Many lymphomas
in this category present with translocations of both MYC
and BCL2 and/or BCL6 (double or triple hit) and have a
very aggressive clinical course [5]. The second provisional
category recognizes cases that usually occur in the
mediastinum and have features of both CHL and DLBCL,
usually primary mediastinal large B cell lymphoma
(PMBL). Although in most cases one or the other diagnosis
can be made, there seems to be a true biological “gray-
zone” between the two entities. Indeed gene expression
profiling revealed striking similarities between CHL and
PMBL [6, 7]. Although this category includes mainly
lymphomas in young patients with mediastinal disease,
similar cases have been reported in peripheral lymph
nodes as a primary site in the adult population. The
tumor cells in these cases exhibit an immunophenotype
with transitional features between CHL and PMBL [8].
These lymphomas generally have a more aggressive
clinical course and poorer outcome than either CHL or
PMBL. A third group of gray-zone lymphoma, although
not explicitly included as a provisional category in the
2008 WHO classification, deals with the relationship
between nodular lymphocyte predominant Hodgkin lym-
phoma (NLPHL) and T-cell/histiocyte-rich large B cell
lymphoma (THRLBCL). Although both entities have
distinctive clinical presentations and morphological fea-
tures in the vast majority of cases, patients with NLPHL
may show features of THRLBCL in initial or subsequent
biopsies, which raises the question whether a diffuse
variant of NLPHL might represent THRLBCL or whether
NLPHL can progress to THRLBCL [9]. Because NLPHL
and THRLBCL are both derived from follicle center B
cells, problems in the differential diagnosis may occur.
The immunophenotype of the tumor cells does not differ
significantly; however, recognition of the small reactive B
cellbackgroundandthegrowthpattern(nodularvs.diffuse)is
of great help in the differential diagnosis. Nevertheless, there
are cases of NLPHL with paucity of small B cells in the
background and areas with a diffuse growth pattern and cases
of THRLBCL with a nodular growth pattern of CD20
+ tumor
cells with few small reactive B cells, making distinction of
the two entities difficult [10].
A fourth group of gray-zone lymphoma may be iden-
tified. This group is more heterogeneous than the others.
Rather than having a basis in true biological overlap, it
reflects diagnostic uncertainty. This group encompasses
cases of EBV
+ lymphoproliferations, including some cases
of Hodgkin lymphoma and the newly recognized category
of EBV-positive DLBCL of the elderly [11].
The European Association for Hematopathology (EAHP)
and the Society of Hematology (SH) organized a workshop
during the XIV Meeting of the EAHP held in Bordeaux,
France in September 2008, in order to better characterize the
pathologic features of gray-zone lymphomas, to clarify
boundaries between these lymphomas and other well-
defined lymphomas and highlight areas that require further
study. One hundred and forty-five cases were received and
reviewed by a panel of experienced hematopathologists. The
cases submitted were initially categorized into four groups:
1. Overlap between Burkitt lymphoma and diffuse large B
cell lymphoma
2. Primary mediastinal B cell lymphoma, mediastinal
gray-zone lymphomas (MGZL), and cases with atypical
immunophenotype
3. Gray zone around nodular lymphocyte predominant
Hodgkin lymphoma, T-cell/histiocyte-rich large B cell
lymphoma, and classical Hodgkin lymphoma
4. EBV
+ lymphomas, lymphomas occurring in HIV
+
individuals, and posttransplant lymphoproliferative
disorders (PTLD)-related B cell lymphoproliferations.
The workshop forum provided a unique opportunity for
open—and often lively—discussions between case submit-
ters, the panel, and the other participants. The main topics
of the discussions included ambiguities in the terminology
and classification of different lymphomas under the
umbrella of gray zone offering the opportunity to discuss
the conclusions of the recent 2008 WHO Classification of
Tumors of Hematopoietic and Lymphoid Tissues. The
following report summarizes the discussions and conclu-
sions emerging from the Workshop.
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large B cell lymphoma (session 1)
The overlap between BL and DLBCL has been a matter of
controversy among pathologists and clinicians, as well as
between both groups. Separation of the two entities is
considered relevant because treatment decisions are based
on the different diagnoses, and prognostic impact is
implied. Based on biological and clinical information
gathered over the past few years, the subject was
thoroughly re-evaluated for the fourth edition of the WHO
classification, and some distinct decisions on classification
were made [1]. Consequently, the possible overlap or gray
zone between BL and DLBCL was chosen as one of the
subjects of the EAHP workshop. In this section, we will
review the background of these decisions, the newly set
definitions, and the specific issues of differential diagnostic
problems as were highlighted by the submitted cases.
Approach for classification in the WHO classification
For the fourth edition of the WHO classification, an attempt
was made to retain the “clean entities.” Thus, BL and
DLBCL were very narrowly defined based on morphology,
immunophenotype, and genetic alterations in order to set
very distinct biological entities with distinct clinical features.
Terms like “Burkitt-like lymphoma” and “atypical BL” were
eliminated since this terminology has led to much confusion
in the past, mainly due to the fact that definitions were never
clearly set and individual authors have used them in different
ways. Inevitably, the choice implies that a larger number of
cases will fall outside these narrow definitional boundaries
and remain unclassifiable. To accommodate these cases, a
novel category was established, “aggressive B cell lympho-
ma, unclassifiable with features intermediate between BL
and DLBCL” [2]. This group should not be regarded as an
entity but as a provisional sanctuary for differential diag-
nostic problems that await results from ongoing research to
provide a sound scientific basis for future classification.
Burkitt lymphoma
Three clinical variants of BL have been recognized: the
endemic form (also called African type), the sporadic or
nonendemic form, and the immunodeficiency-related form
(mostly HIV-associated). The endemic form is generally
found in boys under the age of 10 years in the jaw or in the
abdomen. This lymphoma is EBV positive in 100% of the
cases. Recent investigations in Africa suggest that other
epidemiologic pathogenetic cofactors might also play a
role. The sporadic variant is observed everywhere in the
world and affects boys between 5 and 15 years old. In the
Western world, it is the most frequent lymphoma in
children with 45%, in contrast to only 1–2% in adults. In
most patients, the tumor presents in the ileocecal region, but
other mainly extranodal (abdominal) localizations are
observed. Extensive meningeal and bone marrow involve-
ment can been seen. Patients may present with fully
leukemic, fully “solid,” or combined patterns. The HIV-
related form is very often predominantly nodal. EBV is
present in 20–30% of all cases [12–14].
Typically, BL has a cohesive growth pattern with
squared-off cell borders, and usually a starry-sky pattern is
seen. The cells have a deeply basophilic cytoplasm with lipid
vacuoles (Fig. 1a, f) The nuclei are medium-sized and are
smaller than or similar in size to histiocyte nuclei. In well-
preserved cases, the nuclei are round and contain a finely
clumped chromatin and multiple medium-sized paracentral
nucleoli. In the new definition of BL, some morphological
variation is accepted to include a more pronounced range in
nuclear size and presence of large central nucleoli, as were
previously included in “atypical BL.” Much of this
variation may be caused by differences in preservation
and fixation, as well as by interobserver interpretation.
Indeed, since gene expression studies suggest complete
overlap, classical and atypical morphologies were lumped
together in the new WHO classification [15, 16]. In spite of
this morphologic diversity, the immunophenotype and
genotype are very narrowly defined with high expression
of CD20, surface IgM without IgD, and homogeneous
expression of CD10, BCL6, CD77, CD38, and absence of
BCL2. IRF4/MUM1 may be expressed in some cases but is
generally weakly expressed (Fig. 1c–e, g, h). Expression of
terminal deoxynucleotidyl transferase should be absent.
The genetic basis of BL is defined by a translocation in-
volving one of the immunoglobulin genes (IG)a n dMYC in
the context of a very limited number of additional aberra-
tions (simple karyotype; Fig. 1l). In 40% of the cases, no
additional cytogenetic abnormalities are identified. This can
be appreciated by conventional karyotyping but also by
methods like comparative genomic hybridization (CGH)
array [17]. In the majority of the cases, IGH is found as a
translocation partner, whereas in approximately 15% of the
cases IGL or IGK is found [18]. All MYC/8q24 breaks can
be detected best using fluorescent in situ hybridization
(FISH), which is applicable to formalin-fixed paraffin em-
bedded (FFPE) tissue sections [19]. Classical karyotyping
remains very helpful since the yield is high and the results
give information on not only the translocation but also on the
genetic complexity caused by other structural and/or numer-
ical abnormalities [18]. Independent studies have shown that
geneexpressionprofilesareverycharacteristicforBL[15, 16].
In the workshop, four cases of BL were submitted that
highlighted the morphological spectrum. Of this small
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(submitted by R. Felgar), and aberrant CD4 expression was
seen in an HIV-associated case (submitted by G. Fan).
Diffuse large B cell lymphoma with features
of Burkitt lymphoma
In adult patients of Western countries, DLBCL represents
almost 40% of all NHL, whereas in pediatric patients it
accounts for up to 10–20% of all NHL. Various subtypes of
DLBCL can be discerned, however, DLBCL, not otherwise
specified still remains a mixed bag with a highly divergent
clinical presentation, morphology, phenotype, and molecu-
lar background.
In less than 10% of the cases, differential problems with
BL may be considered (Fig. 1b). These cases often show a
cohesive growth pattern without any stromal reaction or
admixture with reactive T cells, a high proliferation rate,
numerous apoptotic bodies, and a starry-sky pattern [20].
However, in the absence of typical or atypical BL cellular
Fig. 1 a Burkitt lymphoma.
Note the typical morphology of
BL cells and the starry-sky
pattern. b DLBCL. The mor-
phology of this case is consis-
tent with a diagnosis of DLBCL.
In case of an appropriate immu-
nophenotype and genetic back-
ground, a diagnosis of (atypical)
Burkitt lymphoma with plasma-
cytoid differentiation may be
considered. The case illustrates
the morphological overlap be-
tween BL and DLBCL. c–g
Cytological features and immu-
nophenotype of BL. Note the
strong positivity of the tumor
cells for CD10 (c) and BCL6
(d). The proliferation rate is
almost 100% as demonstrated
by MIB-1 staining (e). The
cytological features are charac-
teristic of BL (f). BCL2 is
negative on tumor cells in the
presence of positive T cells as
internal control (g). h In con-
trast, note the strong BCL2
positivity, suspicious of dual
translocation (double hit). i Ses-
sion 1, interphase FISH showing
MYC trisomy and possibly am-
plification (IGH green, MYC
red). j Session 1, BCL6 dual-
color break apart FISH showing
a BCL6 break. k Session 1,
complex karyotype with multi-
ple structural alterations, ampli-
fications, and deletions.
l Session 1, simple karyotype,
only showing t(8;14) and
trisomy 12
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and cases with an unambiguous large cell morphology,
“empty” vesicular nucleus, and multiple large nucleoli and/
or abundant cytoplasm should rather be regarded as
DLBCL, irrespective of the immunophenotype. Many of
these cases do have a BL immunophenotype and may be
negative for BCL2. Therefore, any tumor with a BL
immunophenotype still requires the morphological and
genetic context of BL in order to render this diagnosis.
In all DLBCL together, 8q24/MYC rearrangement is seen
in 5–15% of the cases; however, in cases of DLBCL with
features of BL, it increases up to 40% of the cases. Usually,
such cases have a complex karyotype and many have a
MYC breakpoint with non-IG partners (Fig. 1k). Such non-
IG breakpoints are detected by an 8q24 segregation FISH
assay but not by an 8q24–14q32 FISH fusion assay.
DLBCL with a MYC breakpoint generally have a relatively
poor outcome, and thus it has been advised to assess such
breakpoints in all cases of DLBCL, irrespective of
morphology [21, 22].
Several examples were submitted to the workshop,
including a case with a highly complex karyotype with
three copies of MYC, four copies of BCL2 and a BCL6
rearrangement, and a case with high-level amplification of
MYC, submitted by N.L. Harris. In almost all submitted
cases that were considered as DLBCL, CD10 was negative.
The biological relevance of separating BL from DLBCL,
according to the current definitions, is supported by gene
expression [15, 16] and array CGH studies [17]o fMYC
+
DLBCL, DLBCL with a BL immunophenotype, and typical
BL. Nevertheless, debatable cases still occur. Importantly,
little solid information is available on the clinical relevance
of this differential diagnosis. Accordingly, results from the
MRC/NCRI/Ly10 clinical trial treating all BL and all
highly proliferative DLBCL as BL suggest that the results
in the DLBCL were not better than expected for treatment
with rituximab, cyclophosphamide, adriamycin, vincristine,
and prednisone (R-CHOP) [23].
The phenotypic spectrum of Burkitt lymphoma
BL has a characteristic immunophenotype, and the majority
of the relevant markers for the differential diagnosis can be
demonstrated on FFPE material (Fig. 1c–e, g, h). In contrast
to the previous WHO classification, weak BCL2 expression
isconsideredacceptableinBL.However,itshouldberealized
that the normal counterpart cell of BL, the early germinal
center B cell, does not express BCL2 and, therefore, another
explanation should be found for this expression. For that
reason, extensive ancillary studies are always indicated. Most
importantly, a “double-hit” lymphoma (see below) should be
actively excluded. Another explanation for (weak) BCL2
expressionmaybeupregulationbyEBV,andinEBV
+ cases a
diagnosis of BL would be fully acceptable in the presence of
the correct genetic context. A prime example was submitted
as a case with BL morphology with uniform positivity for
CD10 and BCL6, but separate areas with a divergent
immunophenotype of BCL2
+/IRF4/MUM1
− versus BCL2
−/
IRF4/MUM1
+ (submitted by M. Ashton-Key). The diagno-
sis of BL was supported by the presence of the t(8;14), in the
context of a simple karyotype (Fig. 1l). Similar consider-
ations were present in a case submitted by G. Fan that lacked
Bcl-6 expression but that was otherwise typical of BL. IRF4/
MUM1 was found to be heterogeneous and noncontributory
for classification.
Burkitt lymphoma without demonstrable
MYC translocation
Currently, most MYC breakpoints are detected using FISH.
In about 10% of all BL, including pediatric cases that
otherwise fulfill all criteria, no 8q24/MYC breakpoint can
be demonstrated using this technique [19, 24]. Of note, in-
depth analysis may show MYC alterations with very small
insertions/deletions or breakpoints that are located so far
away from the gene that they are missed with standard
FISH assays. So it is unknown how many cases of true BL
really lack any MYC rearrangement or mutation. Copy
number increase or amplification of MYC has been
proposed as an alternative mechanism, but this phenome-
non may be more indicative of a DLBCL than BL [25].
There is also one recent report suggesting that deregulated
microRNAs may cause overexpression of MYC and can
lead to a BL or a lymphoma-mimicking BL [26].
Two cases showing high level of MYC amplification
were submitted to the workshop. The cases submitted by J.D.
Nuckols (Fig. 1i) was diagnosed as DLBCL based on mor-
phology and immunophenotype, whereas the case with sev-
eral copies of MYC submitted by N.L. Harris showed a BL
morphology and immunophenotype. Following the basic
concept of the WHO classification of keeping well-set, clean
entities, cases with MYC amplification, as well as those com-
pletely lacking 8q24/MYC alterations, should not be regarded
as BL but rather be kept in the provisional category of B cell
lymphoma, unclassifiable, with features intermediate between
DLBCL and BL, or alternatively they should be diagnosed as
DLBCL, if the morphology is typical of this entity.
In conclusion, one likely has to accept rare cases of true
BL that fulfill all epidemiological, clinical, histopatholog-
ical, immunological, and molecular features of BL but,
nevertheless, do not have a demonstrable MYC breakpoint.
“Double-hit” lymphomas
The “double-hit” lymphomas are characterized by a second
translocation in addition to a t(8;14), t(8;22), or t(2;8). In
J Hematopathol (2009) 2:211–236 215general, the 8q24/MYC breakpoint is often a secondary alter-
ation in these lymphomas. In the majority of the cases, a
18q21/BCL2 breakpoint can be found, mostly as a t(8;14)+t
(14;18) karyotype, but sometimes as a complex translocation
on a single chromosome t(8;14;18). Based on the molecular
structure of the t(14;18), it can be assumed that this break-
point has been the primary alteration caused by aberrant VDJ
recombination in a precursor B cell. This event is followed
by the 8q24/MYC translocation mediated by AID in the
germinal center cell stage. Indeed, similar 8q24/MYC
alterations are sometimes seen during follow-up in patients
with follicular lymphoma leading to transformation to highly
aggressive disease [5, 27–29]. Two such cases with a history
of FL were submitted to the workshop. This type of “double-
hit” lymphoma is characterized by a morphology that may
completely mimic BL but with frequent BCL2 expression.
All together, six cases representing MYC/BCL2 double-
hit cases were submitted to this workshop. These cases
showed an immunophenotype with strong expression of
CD10, BCL6, and BCL2. Analysis of IRF4/MUM1 was not
helpful. Since both IG loci may be involved in the two trans-
locations, IG expression may be absent in such cases [30].
Most importantly, the frequency of this diagnosis is
steadily increasing with age and may increase to more than
one third of all aggressive lymphomas with features of BL
in patients over 60 years of age [18]. Therefore, the finding
of a BCL2 protein-positive BL, especially in an elderly
patient,shouldprompta verycareful searchfor a “double-hit”
status (Fig. 1h). The clinical course of 18q21/BCL2 +8 q 2 4 /
MYC double-hit lymphomas is extremely poor, and the dis-
ease respondsratherpoorlytobothDLBCL-directedR-CHOP
and BL-oriented “high-intensity–short-duration” treatment.
Much more rarely, 8q24/MYC alterations are seen in
combination with 11q13/CCND1 and 3q27/BCL6 break-
points. Examples of such cases were submitted by S.
Dufresne and C. Keller (Fig. 1j). Even “triple-hit” cases of
18q21/BCL2+8q24/MYC/3q27/BCL6 breakpoints may oc-
cur, of which one case was submitted in the workshop by
D. de Vinck. In contrast to 18q21/BCL2 and 11q13/CCND1
that can both be regarded as primary alterations, the
sequence of events is less clear for 3q27/BCL6 and also
little is known about the clinical consequences or prognosis
of these patients. The immunophenotype (BCL2
+, CD10
+,
BCL6
+) seems to be rather similar to the cases with an
additional 18q21/BCL2 alteration, as was supported by the
three submitted cases.
B cell lymphoma, unclassifiable, with features
intermediate between diffuse large B cell lymphoma
and Burkitt lymphoma
The diagnosis of B cell lymphoma, unclassifiable, with
features intermediate between DLBCL and BL was coined
for those cases that do not fit into the well-set category of
BL but also show such features that would make it inappro-
priate to just lump them into the category of DLBCL. Many
of the difficult differential diagnostic problems, as dis-
cussed during the workshop, indeed belonged to this
category. Thus far, “double-hit” lymphomas represent the
best-defined subgroup of this category. This group is an
example of how increasing biologicalinsight helps to define a
distinctive disease entity and assists in recognizing its
morphologicalspectrumandimmunophenotype.Fortheother
subgroups of this category, additional biological and clinical
information will be needed to come to a better classification.
From a practical point of view, a multidisciplinary discussion
for treatment planning is mandatory in all these cases.
Treatment decisions should not only depend on the classifi-
cation by the pathologist but also on the clinical situation.
Mediastinal gray-zone lymphoma and other lymphomas
with atypical immunophenotype (session 2)
This session was devoted to MGZL and other lymphomas
with atypical immunophenotype that caused differential
diagnostic problems, often between CHL and NHL. An
emphasis was placed on MGZL given that, at the time of
the workshop, the 2008 WHO classification was newly
published with the new category of B cell lymphoma,
unclassifiable, with features intermediate between DLBCL
and CHL (herein denoted BCLu) [3]. In this section, we
will briefly review primary mediastinal large B cell
lymphoma (PMBL) and the concept of MGZL in order to
provide the framework for the cases submitted that were
related to this general topic. We will also discuss selected
key diagnostic issues related to the other submitted cases of
lymphomas with atypical phenotypic findings.
Primary mediastinal large B cell lymphoma
Primary mediastinal large B cell lymphoma was described
in 1980 from a review of 184 adult NHLs. A group of 17
cases was identified that manifested as a mediastinal mass
with diffuse aggressive histology [31]. Since this initial
description, the features of typical PMBL have been well
characterized [32–34].
Often presenting in younger women, these lymphomas
present as a rapidly enlarging mediastinal mass with symp-
toms related to compression of thoracic structures. Histo-
logically, this lymphoma is composed of an infiltrate of
large cells with round or lobulated nuclei. The cells often
have abundant clear cytoplasm. There is background com-
partmentalizing sclerosis. Occasional multinucleated RS-like
cells can be seen. While the architecture is usually diffuse, a
minority of cases (30%) may show focal nodularity. Necrosis
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The immunophenotype is that of a mature B cell expressing
CD20 and other pan B cell markers such as CD79a and
PAX5 but lack surface immunoglobulin expression [36, 37].
The B-cell-associated transcription factors OCT-2 and
BOB.1 are also strongly expressed [37]. CD30 is expressed
in most cases, albeit with variable intensity [32, 35]. TRAF-1
and cREL are expressed in PMLBL, unlike other DLBCLs,
and reflects activation of the nuclear factor kappa B pathway
[38]. The cells are variably positive for germinal center
markers BCL6 and CD10 and also express other markers
such as CD23. The former two markers have been taken as
evidence of germinal center derivation, and the latter,
expressed in up to 85% of cases, has been taken as evidence
of possible thymic B cell derivation [39, 40]. Although these
characteristic pathologic features have been identified, none
are entirely specific for PMBL. Thus, further proof that
PMBL was indeed a specific type of aggressive large B cell
lymphoma distinct from nodal DLBCL was needed. Appli-
cation of molecular techniques confirmed that PMBL was a
distinct entity. For example, it has been demonstrated that
PMBL has characteristic genomic imbalances that include
gains at chromosome 9p13.1–9p13.3 (approximately 70% of
cases), 9p23-p24 (approximately 60% of cases), and 2p15-
p16.1 (area of REL and BCL11A, approximately 60%), as
well as losses [41–43]. Loss at chromosome 1p13.1-p13.2
has been reported in up to 43% of cases [44]. Gene
expression profiling studies have also shown that PMBL
has a distinct profile compared to diffuse large B cell
lymphoma, and several highly expressed genes including
MAL, CD23, FIG1, TARC, NFkB2,a n dPDL1/L2 have been
identified [6, 7, 45, 46]. Indeed, molecular similarities were
noted between PMBL and another lymphoma that charac-
teristically occurs in the mediastinum CHL [6, 7]. Four cases
of PMBL were submitted; two were from the mediastinum
and two were from cervical lymph nodes, but it was unclear
whether a mediastinal mass was present (Table 1). The
features of the latter, however, were consistent with PMBL,
including MAL expression. One case showed a nodular
growth arising from the thymus (Fig 2a). The atypical cells
showed a B cell immunophenotype but had some RS-like
cells that expressed strong CD20, CD30, OCT-2, and BOB.1
but lacked EBER (this was also the case that lacked MAL
expression). The second case was felt to be morphologically
and phenotypically classic for PMBL with a diffuse
histology and large cells expressing CD20, PAX5, and
MAL (Fig 2b–d). One case added the twist of aberrant Tcell
marker expression (such as weak CD3) but lacked TRG@
rearrangement while showing IGH@ rearrangement
(Fig. 3c–g).
Mediastinal gray-zone lymphoma
The similarities between PMBL and CHL had been
recognized both from the clinical as well as histopathologic
perspectives. Reports of sequential or composite CHL and
Table 1 Summary of the clinical features and immunophenotype of mediastinal lymphomas (session 2)
PMBL (N=4) Mediastinal “gray-zone”
lymphoma (N=7)
Composite lymphoma:
CHL and DLBCL (N=4)
Demographic information
Age range 21–48 25–85 22–54
Sex 4F 6 M, 1F 4F
Site Mediastinal and/or cervical Mediastinal and/or
cervical, 1 inguinal
Mediastinal
Immunohistologic markers
CHL-like areas PMBL-like areas
CD45 3/3 3/5 0/3 3/3
CD20 4/4 6/7 2/4
a 4/4
CD30 4/4 7/7 4/4 3/4
CD15 0/4 4/7 4/4 0/4
PAX5 3/3 4/7 3/3
a 3/3
OCT-2 2/2 3/5 0/3 3/3
CD23 ND 2/3 0/3 3/3
MAL 3/4 4/6 2/2 4/4
EBV (EBER) 0/4 1/6 4/4 4/4
PMBL primary mediastinal B cell lymphoma, CHL classical Hodgkin lymphoma, DLBCL diffuse large B cell lymphoma, EBV Epstein–Barr virus,
ND not done
aWeak expression
J Hematopathol (2009) 2:211–236 217NHL have been recognized [47, 48], and cases of
mediastinal lymphoma with features of both a DLBCL
and nodular sclerosis (NS) HL have also been reported
[49]. Since these earlier reports, the occurrence of medias-
tinal lymphomas with features of both B cell NHL and
CHL has been described and has been termed mediastinal
gray-zone lymphoma [8, 50, 51]. In the largest series to
date, 21 cases were characterized and two subtypes were
identified [8]. Some cases had a morphology resembling
CHL but had atypical features such as increased numbers of
large mononuclear cells, lack of the typical mixed inflam-
matory background, and atypical immunophenotypic char-
acteristics of the Hodgkin-like cells such as strong
expression of CD20. The other subtype had morphology
of PMBL with diffuse monomorphous large cells. Back-
ground compartmentalizing sclerosis was often present, and
there was usually only a sparse inflammatory background.
If a mixed inflammatory infiltrate was present, it was only a
focal component. Occasional nodules or areas with RS-like
cells or lacunar cells were present. The immunophenotype
was atypical and had features suggestive of CHL. For
example, CD20 was often only weakly expressed or absent
Fig. 2 a–d Session 2, case 38:
A typical example of a primary
mediastinal large B cell lym-
phoma arising from the thymus
(a). Session 2, case 27 illustrates
a primary mediastinal B cell
lymphoma with large pleomor-
phic cells embedded within a
background of sclerosis (b) that
expresses CD20 (c) and CD30
(d) but lacks expression of
CD15. e–i Session 2, case 1
shows a mediastinal “gray-
zone” lymphoma demonstrating
histologic features typical of
primary mediastinal large B cell
lymphoma (e) but with an atyp-
ical immunophenotype with ex-
pression of weak CD30 (f) and
moderate to strong CD15 (g).
The lack of CD20 among the
large atypical cells (h) favors
classical Hodgkin lymphoma
whereas strong expression of
PAX5 (i) favors a large B cell
lymphoma
218 J Hematopathol (2009) 2:211–236in many cases, and CD15 was expressed at least focally in
60%. B cell transcription factors (PAX5, OCT-2, BOB.1)
were usually expressed, albeit often weakly, in 13/14 cases
in which all were evaluable. Finally, MAL was expressed in
seven of nine cases [8].
Recognizing this phenomenon, the 2008 WHO classifi-
cation included a chapter defining an “overlap” lymphoma:
BCLu [3]. These lymphomas are present most commonly in
younger males (age 20–40) with mediastinal involvement,
although nodal sites may also be involved, with pathologic
features described above. Although it is uncertain whether
it is a related process, composite CHL and PMBL or
sequential CHL and B cell lymphoma (in either order) is
also recognized [3], although it is uncertain whether the
biology underlying these composite or sequential lympho-
mas is related to the phenomenon of BCLu.
Seven cases of mediastinal gray-zone lymphoma were
submitted (Table 1). Two cases represented mediastinal
masses considered as examples of BCLu. The case
presented by E. Hsi had the histology of a mediastinal
large B cell lymphoma but had an atypical immunopheno-
type. Whereas the expression of strong CD45, CD79a,
CD30, strong PAX5, and MAL might favor PMBL, lack of
CD20 and B cell transcription factors OCT-2/BOB.1 with
expression of CD15 is reminiscent of CHL (Fig 2e–j). The
case presented by R. Gascoyne showed histology more in
keeping with CHL but also showed hybrid phenotypic
features (strong CD20
+, CD45
+, CD79a
+, focal CD30
+,
Fig. 3 a, b Session 2, case 11
represents an example of a
composite lymphoma and illus-
trates distinct areas resembling
classical Hodgkin lymphoma
and primary mediastinal B cell
lymphoma. The classical
Hodgkin-like areas exhibit large
atypical cells with Reed-
Sternberg cell morphology (a),
whereas the primary mediastinal
B cell lymphoma-like areas
show sheets of large atypical
cells embedded in a fibrotic
stroma (b). c–i Session 2, case
20 shows an example of classi-
cal Hodgkin lymphoma with
aberrant T cell marker
expression. The large
Reed-Sternberg-like cells
(c) express multiple T-lineage
markers including CD3
(d), CD5 (e), and CD4 (f), in
addition to weak expression of
the B cell transcription factor
PAX5 (g)
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additional case illustrated how modern practice of needle
biopsy may affect the pathologist’s ability to fully evaluate
a case. In this case, a needle biopsy of a large mediastinal
mass showed features compatible with NSHL; however, a
repeat biopsy after only one cycle of chemotherapy showed
mediastinal gray-zone features with sheets of mononuclear
Hodgkin-like cells and sclerosis in a mixed inflammatory
background. Immunophenotyping showed expression of
CD30, OCT-2, BOB.1, CD20, and MAL. Additional
variations of BCLu were seen in cases submitted by Drs.
Alobeid, Chen, Imai, and Völker. The latter case was from
an inguinal lymph node and added a further variation of not
being from a mediastinal site. In summary, the 2008 WHO
classification category BCLu was created to recognize the
biologic overlap between some cases of B cell lymphoma
and CHL, in particular the mediastinal gray-zone cases, and
several illustrative cases were submitted that covered the
morphologic and immunophenotypic spectrum. These
include cases with morphology of CHL but immunophe-
notype more in keeping with PMBL and vice versa. The
use of B cell transcription factor markers in the evaluation
of these cases including PAX5, OCT-2, and BOB.1 is
helpful and sometimes necessary, in addition to standard
markers for CHL and DLBCL. Of interest, MAL expres-
sion is usually seen in such cases.
Composite PMBL and CHL
As noted previously [8], composite PMBL and CHL
occurs, and this was illustrated in four cases submitted to
this workshop (Table 1). The case presented by A. Dogan
showed clear areas typical of either DLBCL or CHL and
after treatment with R-CHOP, the patient relapsed with the
CHL component (Fig 3a, b). Interestingly, in two cases with
composite areas in a mediastinal tumor, one showed MAL
expression in both components, whereas in the other case
MAL expression was only seen in the mediastinal large B
cell lymphoma component. The pathologic features in the
submitted cases were consistent with what has been
published. As one might expect from its relationship to
PMBL, most cases expressed MAL protein. These cases
help clarify diagnostic issues related to mediastinal lym-
phomas. Specifically, one should strive to separate PMBL
from CHL, and this can be done in most cases using the
presence of typical morphology, supported by characteristic
immunophenotypic data. Morphologic variations such as
presence of RS-like cells in PMBL or sheets of mononu-
clear RS variants in CHL are acceptable and should not
prompt the use of the BCLu designation. Similarly, minor
immunophenotypic variation such as strong CD20 expres-
sion in otherwise typical CHL should not prompt the use of
the BCLu designation. An expanded immunophenotypic
panel that includes use of markers such as CD23, PAX5,
OCT-2, BOB.1, and MAL (if available) may help clarify
how much overlap is present. The panel agreed that further
work is needed to define better the boundaries between
CHL and BCLu on one hand and to define acceptable
phenotypic variation in CHL on the other hand. Finally,
composite PMBL and cHL cases can be recognized when
adequate sampling is present and reminds us of the
problems that may be associated with the use of needle
core biopsies for primary diagnosis. Importantly, composite
cases containing distinct PMBL and CHL areas should be
designated as composite lymphomas and not included in
BCLu.
Classical Hodgkin lymphoma with immunophenotypic
deviations
Another set of cases reviewed in session 2 had the theme of
CHL with an unexpected immunophenotype. The case
presented by E. Haralambieva was an axillary lymph node
biopsy from a 38 years old with typical CHL morphology
but strong CD20 expression in the RS cells. Other B-
lineage markers such as CD79a and B cell transcription
factors (PAX5, OCT-2) were negative. Another case
illustrated a typical CHL case with MAL expression.
MAL expression in CHL has been shown to be present in
up to 20% of cases and associated with shorter survival
[52]. Three cases were examples of CHL with aberrant T-
cell-associated markers, a rare but reported phenomenon
[53]. The case from U. Zanetto was particularly interesting,
as in addition to the characteristic weak PAX5, CD15, and
CD30, multiple T cell markers (CD2, CD3, CD4, and CD5)
were also expressed in the RS cells (Fig 3c–i).
DLBCL with unusual immunophenotype
Seven cases could be grouped as DLBCL with unusual
phenotype. Of these, three cases were cyclin D1 positive
that lacked CCND1 rearrangement and did not appear to
represent blastoid variants of mantle cell lymphoma. These
rare cases have been the subject of recent study. Some cases
may have additional copies of CCND1 by FISH analysis as
a possible mechanism for overexpression, although cases of
DLBCL with extra copies of the gene without protein
overexpression do occur [54, 55]. Two cases with aberrant
T-cell-associated antigen expression were also submitted
along with two cases with unusual morphology and/or
immunophenotype. The case from M. Kinney was felt to be
related to an anaplastic variant of DLBCL occurring in a
34-year-old woman with laboratory findings of an under-
lying autoimmune process (antinuclear antibody). Anaplas-
tic CD30
+/EBER
+ B cells were present in a sinusoidal
pattern in a background of follicular hyperplasia and
220 J Hematopathol (2009) 2:211–236polytypic plasmacytosis and was reminiscent of a series of
sinusoidal CD30
+ large B cell lymphomas published
previously [56].
T cell lymphomas with CD30 and/or CD15 expression
Four cases of T cell lymphomas were also submitted. One
case was an ALK
+ anaplastic large cell lymphoma that
expressed Bcl-6, which has been reported in a substantial
minority of cases [57]. Three cases of CD30
+/ALK-
negative anaplastic large cell lymphoma were submitted
that were confirmed to have clonal T cell receptor gene
rearrangement. Two were CD15
+ and expressed other T-
cell-associated markers such as CD4. Expression of CD15
in Tcell lymphomas has been reported in rare cases and is a
potential pitfall in misclassifying a case as cHL [58]. Lack
of the typical mixed inflammatory background of CHL,
presence of other atypical cells without features of Hodgkin
cells, abnormal T cell immunophenotype (loss of pan T cell
markers), and presence of a prominent T cell clone from
whole-tumor DNA extracts are helpful diagnostic clues that
one is not dealing with CHL. The case submitted by E.
Remstein was representative of this problematic area. It had
RS-like cells but lacked a typical mixed background of
CHL and expressed CD4. Of note, all three of these cases
expressed clusterin in the characteristic (albeit not entirely
specific) “dot-like” pattern reported for ALCL, including
ALK-negative ALCL [59, 60]. A minority of DLBCL,
cases of cutaneous T cell lymphoma, and rare cases of
peripheral T cell lymphomas or cHL may express clusterin
[59–61].
The last three groups of cases with atypical immuno-
phenotype illustrate and corroborate the general consensus
that minor immunophenotypic variation (such as moderate/
strong CD20 expression) in otherwise morphologically and
immunophenotypically characteristic CHL should not
prompt the use of BCLu. Furthermore, other immunophe-
notypic variation such as T cell marker expression can be
seen in CHL. An additional twist showing potential
problems in distinguishing T cell lymphoma and CHL
was illustrated, as noted above, by submission of cases
showing CD15
+ T cell lymphoma.
Immunophenotypic changes in transformed
B cell lymphomas
The final group of cases considered in this session was a
group of heterogeneous lymphomas that appeared to occur
as a transformation from prior lymphoma or represented a
relapse event. These cases may have demonstrated a
phenotypic “drift” from the original phenotype, not an
uncommon occurrence. Two cases were diffuse large B cell
lymphomas that expressed CD30 and had Hodgkin-like
cells but also strong expression of other B cell markers such
as CD79a. One case represented a DLBCL arising from a
follicular lymphoma, again with unusual immunopheno-
typic findings such as CD30 positivity in the transformed
areas, but a variety of other B cell markers including OCT-2
and PAX5 showed a range of expression in the large
atypical RS-like cells. The case submitted by E. Jaffe was
an example of DLBCL arising in splenic marginal zone
lymphoma in which there was a history of SMZL with
intervening CHL, followed by the submitted case with
transforming SMZL. This last case pointed out the lack of
well-defined criteria for diagnosing transformation of
SMZL to DLBCL. Finally, we should keep in mind the
possibility of immunophenotypic/morphologic changes
occurring in the setting of relapse or transformation. The
distinction between a second unrelated lymphoma vs.
relapse/transformation will depend on molecular techniques
to establish a clonal relationship and is not usually part of
routine practice.
In summary, this session introduced the participants to
evolving concepts in the area of mediastinal gray-zone
lymphomas and the new WHO terminology. Furthermore,
the submitted cases also illustrated a broad spectrum of
cases in which unusual phenotypic variation could cause
diagnostic problems between specific entities such as
CD30
+ sinusoidal large B cell lymphoma, cyclin D1
+
DLBCL, or DLBCL with T cell marker expression.
Weighing the evidence for lineage assignment and knowl-
edge of such variability are required in order to arrive at the
most appropriate diagnosis in these difficult cases.
Gray-zone around nodular lymphocyte predominant
Hodgkin lymphoma, T-cell/histiocyte-rich large B cell
lymphoma and classical Hodgkin lymphoma (session 3)
Gray zone between NLPHL and THRLBCL
NLPHL, a monoclonal B cell lymphoma, usually presents
with a predominantly nodular or a nodular and diffuse
growth pattern sometimes reminiscent of progressively
transformed germinal centers. The infiltrate resides, in the
nodular areas, within large meshworks of follicular den-
dritic cells. It is mainly composed of small B lymphocytes
with varying numbers of intermingled histiocytes and
epithelioid cells eventually forming small granulomas, and
a proliferation of scattered large neoplastic B cells—the so-
called Lymphocyte Predominant cells (LP cells; previously
known as L&H cells). These blasts have scant to moderate
amounts of pale cytoplasm and often folded or lobated
nuclei and are sometimes very similar to, or even
indistinguishable from, classical Hodgkin cells. Patients
with NLPHL usually present in clinical stages I and II and
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relapses. Two cases submitted to the workshop represented
classical examples of NLPHL (Fig 4a–d, submitted by X.
Zhang) with a nodular growth pattern and scattered CD20
+
CD79a
+ epithelial membrane antigen (EMA)
+ LP cells
surrounded by reactive CD3
+ CD57
+ PD1
+ T cells in a
background rich in small B lymphocytes. In the 2008 WHO
classification, THRLBCL is considered a variant of
Fig. 4 a–d Session 3, case 01: NLPHL. Lymph node with NLPHL
with a characteristic nodular growth pattern (a). LP cells (a, insert) are
strongly positive for CD20 and embedded in a background rich in
small B cell lymphocytes (b). The LP cells are surrounded by reactive
CD57
+ (c) and PD1
+ (d) T cells. e–g Session 3, case 03: NLPHL with
diffuse areas, depletion of background B lymphocytes and IgD
+.
NLPHL with diffuse growth pattern infiltrating a lymph node (e).
Note that the background infiltrate of small B lymphocytes is reduced
(f); however, rosetting of PD1
+ reactive T cells around the LP blasts is
present (f, insert). The LP cells are strongly positive for IgD (g). The
IgD
+ LP cells are surrounding the nodules of reactive small B
lymphocytes. h–i Session 3, case 09: NLPHL with THRLBCL-like
areas. CD20 staining highlights the LP cells with areas of very
reduced (h)o rc o m p l e t el o s so fC D 2 0
+ small B lymphocytes
mimicking THRLBCL (i). j–k Session 3, case 18: NLPHL with
CD15 positivity. Typical case of NLPHL with LP cells positive for
CD20 (j) showing unequivocal strong expression of CD15 in the LP
tumor cells (k). l–n Session 3, cases 07 and 27: NLPHL EBV
+. CD20
staining highlights the typical characteristics of NLPHL (l) where the
LP cells are EBV
+ by EBER ISH (m). Case 27 showed in addition
progression to a DLBCL. Note that the high-grade component (left),
as well as the LP cells (right) are EBER
+ (s)
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spite of a limited number of scattered, large neoplastic B
cells, shows a diffuse growth pattern and usually has a
prognosis similar to that of DLBCL. Morphological and
immunophenotypical studies, however, have shown that the
tumor cells in THRLBCL in many cases do resemble the
LP cells of NLPHL. Because of the similarities in
morphology and immunophenotype between NLPHL and
THRLBCL, a biological relationship between these two
entities has been discussed. In addition, there are cases of
NLPHL with histological progression, in which the process
becomes entirely diffuse, and the morphology is indistin-
guishable from de novo THRLBCL. The question, there-
fore, is whether these cases represent true progression to an
aggressive B cell lymphoma or only “THRLBCL-like”
areas in an otherwise typical case of NLPHL.
Thus, one of the target issues addressed during the
workshop was to define criteria for reliably distinguishing
boundaries between NLPHL and THRLBCL. Although
considered by some authors to represent a continuum
ranging from an indolent (NLPHL) to an aggressive
(THRLBCL) category, genetic evidence supports the
concept of discrete entities [62] that infrequently can
emerge from one another [51]. The WHO classification
sharply defines NLPHL and THRLBCL based on charac-
teristic features inferred by morphology and immunophe-
notype but also defines features that, obviously, are
attributable to progression (the latter in a morphological,
not necessarily clinical, sense). The spectrum of nodular
and diffuse NLPHL, purely diffuse NLPHL, NLPHL rich in
blasts, and NLPHL in possible transition to THRLBCL was
presented and extensively discussed during the workshop,
and some unique NLPHL cases associated with particular
immunophenotypic and infection-associated features were
presented.
NLPHL with diffuse areas, depletion of background B
lymphocytes and IgD
+
Purely diffuse NLPHL is exceedingly rare, and most cases
diagnosed as such in the past would now be classified as
THRLBCL. According to the recommendations of the 2008
WHO lymphoma classification, however, a single nodule of
typical NLPHL, in an otherwise diffuse proliferation, is
sufficient to exclude the diagnosis of de novo THRLBCL.
In these cases, the term NLPHL with THRLBCL-like areas
is recommended.
Altogether, seven cases submitted to the workshop were
characterized by classical nodular areas of NLPHL but also
by other features that might be attributed to progression.
They either showed diffuse areas, with slight nodularity
apparent only after immunohistochemical staining for B
cell markers, or featured a moderate increase of blasts. The
key diagnostic features of NLPHL, however, were present
in all the cases. Although the characteristic background
infiltrate of small B lymphocytes was reduced in some
cases, predominantly in the diffuse areas, and the number of
background T cells was higher, all these lymphomas
featured typical morphological changes encountered in
NLPHL, including CD21
+ and/or CD23
+ meshworks of
follicular dendritic cells. Nevertheless, there were two
remarkable immunohistochemical features recognized dur-
ing the review of these cases (Fig 4e–g, submitted by C.
Temmins). First, in all of the cases showing some features
of morphological progression, IgD was expressed in the LP
cells. Reactivity of the LP cells for IgD has been reported in
roughly one third of NLPHL, and its expression was more
commonly found in young males [63]. Accordingly, all
seven cases of NLPHL with diffuse areas and IgD
expression submitted to the workshop were young males
aged between 4 and 40 years. In fact, the expression of IgD
in the tumor cells is a useful argument against the diagnosis
of de novo THRLBCL. Second, the expression of the PD1
antibody, a novel follicular T cell marker [64], turned out to
be particularly helpful in delineating the presence of T cell
rosetting around the LP blasts even in those cases that were
B-cell-depleted or in which CD57 did not highlight the T
cell rosetting. Furthermore, in contrast to de novo
THRLBCL, which lack follicular T cell rosettes, all cases
with borderline features between NLPHL and THRLBCL
showed T cell rosettes, thus suggesting a biological relation
with NLPHL.
NLPHL with T-cell/histiocyte-rich B-cell-like areas
Interestingly, two additional cases submitted to the work-
shop showed—sometimes discrete—areas entirely depleted
of small background B cells, in which the tumor cells (with
LP features or more reminiscent of peripheral B blasts or
Hodgkin cells) were observed in a background of exclu-
sively T cells (Fig 4h, i, submitted by S. Nam-Cha).
According to the 2008 WHO lymphoma classification,
these are the key defining features of NLPHL with
THRLBCL-like areas. This morphological variant is seen
more frequently in cases with a prominence of extranodular
LP cells and in patients with recurrent disease. The 2008
WHO lymphoma classification recommends considering
cases of NLPHL that progress to a diffuse T-cell-rich
pattern as NLPHL, THRLBCL-like to distinguish them from
primary or de novo THRLBCL. By introducing this term
into the diagnostic algorithm of the NLPHL, Poppema et al.
[65] challenged the classification of many published cases
of NLPHL with “progression” to THRLBCL. In fact, some
studies dealing with the accurate estimation of clinical risk
inferred by the variant morphology in these patients have
provided evidence that these tumors might be associated
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increased aggressiveness [10]. Accordingly, the two
patients with THRLBCL-like areas in the workshop
presented with stage III and IV disease and a history of
multiple relapses. One case was treated as NLPHL and the
other with R-CHOP. Nevertheless, both are alive and free of
disease after several years of follow-up. Importantly, using
the term NLPHL with THRLBCL-like areas in daily
diagnostic practice might prevent overtreatment of these
patients. The use of this terminology, on the other hand,
does not exclude, by itself, the existence of true THRLBCL
cases evolving from (classical) NLPHL. During the
diagnostic workup of the cases, the panel found the use of
the PD1 antibody particularly useful in differentiating
NLPHL with extensive THRLBCL-like areas from
THRLBCL because a large fraction of the background T
cells in NLPHL with THRLBCL-like areas expressed PD1,
while this was not the case in THRLBCL.
In this regard, the case presented by T. Molina especially
highlighted the diagnostic challenges encountered when
dealing with the THRLBCL–NLPHL interface. In this case,
the patient had an original diagnosis of THRLBCL
rendered on a needle biopsy of a retroperitoneal lymph
node. After aggressive treatment, the patient achieved
complete remission. The disease recurred after 5 years with
enlarged lymph nodes that, on histological evaluation,
revealed hyperplastic germinal centers surrounded, and in
part colonized by, tumor cells reminiscent of LP cells. A
diagnosis of NLPHL was made. The case was submitted as
an example of coexisting THRLBCL and NLPHL, never-
theless raising the important issue of whether the first
biopsy was representative (NLPHL with diffuse areas?) and
whether or not a diagnosis of THRLBCL should be made in
a needle biopsy. Unfortunately, in this case, there was no
tissue available to perform a PD1 staining. Furthermore, the
diagnosis of NLPHL in the second biopsy most probably
represents very early morphological changes of the disease.
NLPHL with CD15 positivity
Characteristically, LP cells are positive for CD20, CD79a,
CD75, BCL6, and CD45 in nearly all cases and the EMA is
expressed in more than 50% of the cases. In contrast to the
Hodgkin and Reed-Sternberg cells of CHL, OCT-2, PU.1,
and BOB.1 are coexpressed in LP cells, and CD15 and
CD30 are usually negative. Interestingly, two cases showed
unequivocal expression of CD15 in the LP tumor cells, in
addition to expression of B cell markers (Fig 4j, k,
submitted by D. Norris). CD15 expression is regarded as
one of the hallmark immunophenotypic features of classical
Hodgkin lymphoma. It is worth mentioning that both cases
were also IgD
+, thus again suggesting that the expression of
this antigen might be valuable in recognizing particular
NLPHL subtypes. The practical consequence of the finding
is that the expression of a rather promiscuous antigen like
CD15 does not necessarily preclude the diagnosis of
NLPHL. Conversely, and as shown in session 2, CD15
expression does not by itself point to the diagnosis of
classical HL.
NLPHL EBV
+
According to the 2008 WHO lymphoma classification, one
of the defining characteristics of NLPHL, in contrast to
CHL, is the absence of EBV infection in the LP cells.
Nevertheless, in three NLPHL cases submitted to the
workshop, EBER in situ hybridization (ISH) unequivocally
demonstrated the presence of EBV genomes in the tumor
cells (Fig 4l, m, submitted by Garcia-Cosio). This finding
challenges the view that EBV can occasionally be seen in
some small bystander B lymphocytes but is consistently
absent in the tumor (LP) cells of NLPHL [65, 66]. More
interestingly, one of the cases presented by S. Rodriguez
also featured the transition of EBV-associated NLPHL to
EBV-associated diffuse large B cell lymphoma (Fig 4n). It
is currently unknown whether EBV is involved directly in
transformation of NLPHL into DLBCL in some cases. One
interesting feature of all three cases was that they occurred
in patients over the age of 50 years, thus suggesting the
possibility of impaired immune surveillance as a potential
factor in lymphomagenesis as in EBV-associated DLBCL
of the elderly.
Gray zone between THRLBCL and CHL
According to the criteria of the 2008 WHO classification,
THRLBCL is a DLBCL characterized by a limited number
of scattered, large, atypical B cells embedded in a
background of abundant T cells and histiocytes. The large
tumor cells express B cell markers and BCL6, with variable
expression of BCL2 and EMA and are, as a rule, CD15 and
CD30 negative. An important defining morphological
feature is the absence of T cell rosettes around the tumor
cells and the absence of remnants of B follicles or clusters
of small B lymphocytes. Only one case was submitted to
the workshop representing a classical example of de novo
THRLBCL.
A recently recognized morphological variant of THRLBCL
predominantly infiltrates the spleen with multifocal or micro-
nodular involvement of the white pulp (Fig 5a, b)[ 67].
Morphologically, the cellular composition in the spleen-
scattered large neoplastic B cells in a background of
reactive T cells is similar to that seen in THRLBCL of
the lymph nodes. Three cases were submitted to the
workshop representing this splenic micronodular variant
of THRLBCL. The case presented by L. de Leval
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of the tumor, showed areas with progression to DLBCL
forming clusters and sheets of large neoplastic B cells
(Fig 5d). The tumor cells displayed a characteristic
phenotype (CD20
+, BCL6
+,C D 3 0
−,C D 1 5
−), and the
background lymphocytes were CD3
+,C D 5
+,C D 5 7n e g -
ative, with some PD1-positive intermingled T cells. T cell
rosettes around the large neoplastic B cells were absent or
only rarely found (Fig 5c)[ 64].
Although THRLBCL is a well-defined subtype of
DLBCL, morphologic similarities with and immunohisto-
chemical transitions to CHL have raised the possibility of a
relationship or a gray zone between these two entities [68].
Lim et al. [69] described a subtype of THRLBCL with
features similar to classical Hodgkin lymphoma, where the
tumor cells exhibited the characteristic morphology of
classical Reed-Sternberg cells—large, pleomorphic multi-
nucleated cells containing prominent eosinophilic or
amphophilic nucleoli and abundant cytoplasm. However,
the background was unusual for CHL in that eosinophils,
neutrophils, and plasma cells were absent. Immunopheno-
typically, unlike CHL, the neoplastic cells showed strong—
and particularly uniform—expression of CD20 with coex-
pression of CD79a in 50% of the cases. Expression of
CD30 was frequently observed; however, CD15 was
consistently negative. EBER in situ hybridization was
found to be positive in 50% of the cases. Previous studies
have shown that expression of CD20 and absence of CD15
reactivity are associated with a poorer prognosis in CHL,
suggesting that these cases may be distinct from CHL with
a typical phenotype [70].
The 2008 WHO lymphoma classification sharply defines
CHL and THRLBCL based on characteristic morphological
and immunophenotypical features. Accordingly, cases
Fig. 5 a–d Session 3, case 10:
THRLBCL of the spleen with
micronodular involvement.
Micronodular involvement of
the white pulp of the spleen
characterized by scattered large
neoplastic B cells in a back-
ground of reactive T cells (a).
CD20 expression highlights the
abnormal infiltrating nodules
compared to the normal white
pulp (b). PD1-positive T cells
are scattered and T cell rosettes
around the large neoplastic B
cells are absent (c). THRLBCL
shows areas of progression to
DLBCL (d). e–j Session 3, case
17: B cell lymphoma unclassifi-
able with features intermediate
between DLBCL and CHL.
Lymph node with a diffuse
infiltration (e) and numerous
large cells with typical RS cell
morphology (f). The RS-like
cells are negative for CD15 (f,
insert), strongly and uniformly
positive for CD20 (g), CD79a
(h), Oct 2 (i), and EBER ISH
(j). k–n Session 3, case 20: B
cell lymphoma unclassifiable
with features intermediate be-
tween DLBCL and CHL.
Lymph node with vaguely nod-
ular infiltration reminiscent of
NLPHL but with numerous
large cells with typical RS cell
morphology (k). The RS cells
are strongly and uniformly pos-
itive for CD20 (l), Oct 2 (m),
and EBER ISH (n), in addition
to CD15 and CD30 positivity
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uniform expression of CD20 and Reed-Sternberg-like
morphology, EBV positivity, and a rich background of
reactive T lymphocytes should no longer be classified as
THRLBCL but as EBV-positive DLBCL. Nevertheless, the
2008 WHO classification also recognizes that there are
cases of B cell lymphomas, unclassifiable, with overlapping
clinical, morphological, and/or immunophenotypic features
between CHL and DLBCL in lymph nodes as the primary
site [3]. As with the mediastinal gray-zone cases, one may
encounter cases with RS cells, expression of CD45, a
preserved B cell program (OCT-2
+, BOB.1
+, PU.1
+, PAX5
strongly expressed, unlike the weak positivity found in
CHL), strong expression of CD20 and/or CD79a, and
aberrant expression of CD30 and CD15. Strong and
uniform expression of CD20 (with or without other B cell
markers) in an otherwise typical Hodgkin lymphoma
setting is not enough to place a case into the borderline
category. On the other hand, cases with CD20 reactivity
and absence of CD15 should be diagnosed as gray-zone
lymphoma.
During the workshop, the significance of strong, uniform
expression of CD20 and a preserved B cell program in
cases morphologically resembling CHL was extensively
discussed. Five cases were submitted to the workshop
highlighting problems in distinguishing between CHL and
THRLBCL. All five patients were young males aged
between 19 and 44 years with nodal presentations. In all
cases, there were morphological features of CHL but also
strong expression of B cell markers and a partially or
completely preserved B cell program. Three of the cases
were EBV positive and two were EBV negative. An
example of the complexity of some of these cases was
presented by A. Ramsay (Fig 5e–j). The case corresponded
to a 39-year-old male presenting with lymphadenopathy,
splenomegaly, and pancytopenia. The lymph node featured
numerous large cells with typical RS cell morphology. The
immunophenotype showed that the RS cells were strongly
and uniformly positive for CD20, CD79a, CD30, Bcl-6,
and the transcription factor OCT2 and negative for
CD15 and BOB.1. EBER in situ hybridization was positive.
The possibility of an EBV
+ DLBCL of the elderly in a
young patient was raised. However, the panel felt that this
case rather fulfilled the criteria of a B cell lymphoma,
unclassifiable, with features intermediate between DLBCL
and CHL, based on morphology (CHL) and immunophe-
notype (strong CD20
+, CD15
−). Even more challenging
was the case presented by B. Nelson (Fig 5k–n), of a 44-
year-old man with localized lymphadenopathy. The lymph
node showed CHL morphology; however, the immunophe-
notype was unusual in that the RS cells were strongly and
uniformly positive for CD20, PAX5, and OCT-2 and
partially positive for BOB.1 and CD45; however, CD30
and CD15 were positive. EBER ISH was also positive.
Although the morphology and the expression of CD30 and
CD15 suggested a diagnosis of CHL in this case, the
unusual, uniform, and strong CD20 and PAX5 expression
with a preserved B cell program (OCT-2, BOB.1
+/−) makes
the diagnosis of CHL difficult to render. After extensive
discussions, the panel arrived at the conclusion that cases
with features such as the two cases presented should be
diagnosed as B cell lymphoma, unclassifiable, with features
intermediate between DLBCL and CHL, until data from
more studies are available, revealing whether these cases
represent true biologically borderline cases or whether they
are related to one specific entity. Indeed, the question
remains how these patients should be treated. Keeping
these cases separate will allow further study with the hope
that these issues can be resolved as new data become
available.
EBV-positive lymphomas, lymphomas occurring
in HIV
+ individuals, and PTLD-related B cell
lymphoproliferations (session 4)
This session, which included the highest number of cases,
turned out to be quite heterogeneous. In fact, the submitted
cases corresponded to either recently described entities or
cases which showed deviations from the prototypic
descriptions quoted in the 2008 WHO classification [1].
Thus, they did not strictly fulfill the concept of gray zone
applied to the other sessions of the workshop but focused
attention on differential diagnostic problems or addressed
issues related to the pathobiology of these lymphomas.
Notably, most of these cases showed association with EBV
or other viral agents. Due to their heterogeneity, the cases
were subdivided into eight main groups.
EBV
+ DLBCL of the elderly
EBV
+ DLBCL of the elderly (EBV
+ DLBCL-E) is a
provisional entity in the recent WHO classification. It is
defined as an EBV
+ clonal B cell lymphoid proliferation
that occurs in a patient older than 50 years and without any
known immunodeficiency or prior lymphoma. The work-
shop panel included eight cases in this category. All
occurred in HIV-negative individuals with no previous
history of autoimmune disease and/or immunodeficiency.
The median age was 74.5 years (range 60–84), and the
male/female ratio was 1.66/1. Contrary to what has been
reported in the literature concerning the prevalent extra-
nodal location of EBV
+ DLBCL-E [71, 72], seven of eight
cases presented with lymphadenopathy, while the remain-
ing one had a small-bowel tumor. The clinical course was
known in four patients: three died within the first month
226 J Hematopathol (2009) 2:211–236after the diagnosis and one was in complete remission after
1-year follow-up. The latter had been treated with R-CHOP
(eight cycles), intrathecal methotrexate, and autologous
peripheral blood stem cell transplantation. Although based
on a small series, these figures are in keeping with the
concept that EBV
+ DLBCL-E has a much worse prognosis
than DLBCL, not otherwise specified [71, 73–75].
Morphologically, all but one case were characterized by
a diffuse proliferation of clearly atypical transformed large
cells/immunoblasts associated with scattered Hodgkin/
Reed-Sternberg (HRS)-like elements and variable amounts
of inflammatory cells. Three out of eight cases showed
areas of necrosis. The case presented by C.H. Dunphy had a
more polymorphic population with numerous HRS-like
elements, raising the differential diagnosis of ALCL or
CHL of the lymphocyte depleted type (LD; see below).
Immunophenotypically, the neoplastic cells showed posi-
tivity for at least one B cell marker including CD20 (five of
eight), PAX5 (six of eight), and CD79a (eight of eight).
OCT-2 was detected in seven of eight cases, BOB.1 in six,
BCL6 in four, and IRF4/MUM1 in all. The latter finding
underlines that the submitted cases had either activated
germinal center (GC) or activated post-GC phenotype (as
the one presented by J. van der Walt) [76]. In seven of eight
cases, the neoplastic cells were largely positive for CD30
but negative for CD15. The remaining case expressed both
CD15 and CD30 and showed EBV positivity by EBER ISH
in most if not all neoplastic cells. In this case, the panel
retained the diagnosis of EBV
+ DLBCL-E because of the
absence of obvious HRS cells and the positivity of the
neoplastic cells for CD79a, BOB.1, OCT-2, and PAX5.
Notably, CD15 positivity seldom occurs among DLBCLs
[77] and represents an unprecedented finding in the EBV
+
DLBCL-E setting [71, 73]. EBV infection of the neoplastic
cells was shown by LMP-1 immunochemistry and EBER
ISH in seven of eight and eight of eight cases, respectively.
EBV-encoded nuclear antigen 2 (EBNA2) was recorded in
only one instance; this figure is definitely lower than the one
reported by Oyama et al. in their series (22%) [71]. IGVH@
gene analysis was performed in seven cases; five showed a
monoclonal B cell population, one a polyclonal profile, and
one was not conclusive due to DNA degradation.
One case, presented by J. Burke, merits specific attention
because ofits complexity(Fig6a–f). It occurred in a 65-year-
old male who presented with generalized lymphadenopathy.
A lymph node biopsy showed complete effacement due to a
lymphoid population consisting of large atypical cells, often
with HRS-like morphology. The cells were uniformly
positive for CD20, CD79a, PAX5, BOB.1, OCT-2, CD30,
and LMP1 but negative for CD15, CD45, and T cell
markers. No clonal IGVH@ gene rearrangement was
detected by polymerase chain reaction (PCR). This case
obviously raised the possibility of LDCHL, its phenotype
allowing the straightforward exclusion of ALCL (see above).
After extensive discussion, the panel decided to regard it as
EBV
+ DLBCL-E because of the strong expression of B cell
markers and CD15 negativity, which is also in keeping with
the criteria recently published by Asano et al. [73]. Although
limited in number, the present cases somewhat differ from
those originally reported in Japan [75] and should prompt
further studies in order to determine whether EBV
+ DLBCL-
E is a distinct entity in Western populations. In a small series
from the Midwestern USA, the overall rate of EBV positivity
in otherwise typical DLBCL in older adults was less than
1.1% [78].
In conclusion, DLBCL-E should be distinguished from
infectious mononucleosis-type proliferations (IM) and
CHL. Although IM may display some polymorphism with
HRS-like cells and foci of necrosis, it lacks overt
cytological atypia and consists of a mixture of polyclonal
activated B and T cells. On the other hand, DLBCL-E
differs from CHL because of regular CD79a expression,
frequent CD20 positivity, CD15 negativity, usually strong
PAX5 staining, common detection of the transcription
factors BOB.1 and OCT-2, and possible BCL6 expression.
Finally, the positivity of a DLBCL for CD30 should
encourage the search for EBV by EBERs ISH or LMP-1
immunohistochemistry, although the two features are not
invariably associated.
HIV-associated lymphomas
The WHO classification states that these tumors are predom-
inantly represented by aggressive B cell lymphomas. In a
proportion of cases, they correspond to the initial manifesta-
tion of the acquired immunodeficiency syndrome. These
disorders are heterogeneous and include lymphoid neoplasms
seen in immunocompetent individuals as well as those more
commonly encountered in the setting of HIV infection. The
commonest HIV-associated lymphomas are: BL, DLBCL
(frequently involving the central nervous system), primary
effusion lymphoma (PEL), and plasmablastic lymphoma.
CHL shows increased prevalence in HIV-positive patients.
Peripheral Tcell lymphomas are indeed rare.
Five cases were included in this category. Two of them
represented morphologic examples of plasmablastic lym-
phoma. This entity—that in the previous edition of the
WHO classification had been strictly related to the
occurrence of HIV infection and location in the oral
cavity—can actually develop in patients with other immu-
nodeficiency states as well as at other extranodal sites.
Interestingly, both cases showed some peculiar findings. In
particular, the case presented by R.L. Christensen (Fig 6g–
i)—that had the typical phenotypic profile (CD20
−, PAX5
−,
BCL6
−/+, IRF4/MUM1
+, CD138
+, and EBER
+)—was
diagnosed in the lacrimal gland and characterized by
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and bone marrow (BM) infiltration and carried the t(8;14)
with MYC rearrangement. Involvement of lymph nodes is a
rare event in this setting, but even rarer is the occurrence of
t(8;14), so far recorded in only two cases in the literature
[79, 80]. The other plasmablastic lymphoma revealed an
aberrant phenotype. In keeping with a plasma cell, it was
CD20
−,P A X 5
−,B C L 6
−,I R F 4 / M U M 1
+,C D 3 8
+,a n d
EBV
+. However, it expressed CGET1
+ and PRDM1/
Blimp1
+ while lacking CD138
−, a profile intermediate
between a GC B cell (GCB) and a plasma cell. CGET1 is
a highly restricted marker for a subset of GCB-derived
lymphoma [81], while the lack of CD138 in the presence of
Blimp1 [82, 83] suggests late GC/early plasma cell
differentiation. Notably, such a phenotype was not associ-
ated with t(8;14) as reported by Chuah et al. in a
plasmablastic lymphoma aberrantly expressing CD10 [79].
Of the remaining three cases, one represented an ALK-
negative ALCL associated with DLBCL, as supported by
the phenotypic profiles of the two neoplastic components,
Fig. 6 a-f Session 4, case 03:
EBV
+ DLBCL of the elderly.
The neoplastic population—
provided with some HRS-like
features—is admixed with a rich
reactive T cell component (a)
and expresses CD30 (b), CD20
(c), PAX5/BSAP (d), OCT-2 (e),
and LMP1 (f). g–i Session 4,
case 09: HIV-associated plas-
mablastic lymphoma. The neo-
plasm infiltrates the lachrymal
gland (g; cytological details in
the inset) and shows EBV inte-
gration (h) and Ig kappa mono-
clonality (i) at ISH.j –n Session
4, case 29: Extracavitary PEL in
the absence of immunodeficien-
cy. Lymphomatous cells vary in
size and shape (from immuno-
blastic to plasmablastic; j), are
negative for CD45 (k), express
IRF4 (l), and turn positive for
HHV8 LANA (m) and EBV (n).
o–r Session 4, case 14: Mono-
morphic PTLD. The surgical
specimen (colon) is character-
ized by multiple ulcers (o). The
tumor consists of large cells
with plasmablastic features (p)
and does express LMP1 (q) and
EBNA2 (r)
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+. To the best of our knowledge, such a
composite lymphoma has never been observed in the HIV
setting. Another case, a patient with a long history of HIV
infection, represented a B cell lymphoma unclassifiable
with features intermediate between DLBCL and BL. In
particular, the tumor (corresponding to an ileocecal mass)
consisted of two distinct populations. Of these, one showed
cytological features consistent with BL, while the other was
composed of large cells, partly multinucleated, with a wide
rim of clear cytoplasm, resembling DLBCL primary arising
in the mediastinum. Notably, both components shared the
same BL-like phenotype (CD10
+, BCL6
+, BCL2
−, and Ki-
67 = 100%) and were negative for EBV and t(8;14). The
last case, observed in a 33-year-old HIV-positive individ-
ual, fulfilled the clinical, morphologic, and phenotypic
criteria for the diagnosis of PEL. Notably, besides bilateral
pleural effusion and ascites, it showed lymphadenopathy
and a mass involving the mesentery, large bowel wall,
rectum, and left psoas, as observed in PEL. However, it was
HHV8 LANA negative, a fact that contradicts the definition
of PEL itself. Although two HHV8-negative PELs are
quoted in the literature [84, 85], the panel decided to classify
this case as HIV-related DLBCL. Ideally, molecular studies
to exclude the presence of HHV8 genome could be done in
such cases to exclude aberrant loss of HHV8-LANA.
PEL and DLBCL with plasmablastic morphology
in immunocompetent patients
Three cases were included in this group. In particular, PEL
is a large B cell neoplasm that presents as serous effusions
in the absence of detectable tumor masses, is universally
associated with HHV8 infection, and most often occurs in
the setting of immunodeficiency. Rarely, HHV8
+ tumors
indistinguishable from PEL present as solid masses: they
are termed “extracavitary PEL.” Two cases were consistent
with the diagnosis of extracavitary PEL and notably
occurred in immunocompetent hosts, a finding rarely
encountered in elderly individuals from areas with high
prevalence for HHV8 infection like the Mediterranean [1].
The case presented by C. Bacon (Fig. 6j–n) was a 15-year-
old HIV-negative African boy who developed large cervical
nodes, a mediastinal mass, splenomegaly, and abdominal
lymphadenopathy. Morphologically, the tumor showed a
cytological spectrum from immunoblastic to anaplastic with
some Reed-Sternberg (RS)-like elements that were CD79a
+
(weak), IRF4/MUM1
+, EMA
+, HHV8 LANA
+, HHV8 vIL-
6
+, EBERs
+, CD45
−, CD20
−, PAX5
−, CD138
−, CD38
−,
CD30
−, BCL6
−, T cell, cytotoxic and myeloid markers
−,
Ki-67=90%, and clonal rearrangement by IGK and DH-JH
primers. Comparative genomic hybridization revealed gains
and losses of regions containing PEL-associated genes [86].
The case presented by F. Camacho occurred in a 77-year-
old Spanish male with several chronic diseases. The tumor
presented as an obstructive jejunal mass with plasmablastic
morphology. The tumor cells were CD45
+, EMA
+, CD30
+,
IRF4/MUM1
+, CD138
+, CD38
+, CD20
−, CD79a
-, CD10
−,
BCL6
−,B C L 2
−, and HHV8 LANA
+. The neoplastic
population was EBER
−, a feature that—as mentioned
above—can be seen in old immunocompetent patients from
the Mediterranean area. The third case was seen in an 84-
year-old female with a history of Wolff-Parkinson White
syndrome. She had a 12-cm mass, involving the right psoas
muscle. All clinical and laboratory tests, including the
search for HIV and BM biopsy, were unremarkable. On
microscopic examination, the tumor showed plasmablastic
morphology and had a CD38
+, CD138
+, CD79a
+, PAX5
+,
IRF4/MUM1
+, CD20
−, CD30
−, CD56
−, ALK
−, and BCL6
−
phenotype. ISH displayed cytoplasmic kappa and negativity
for EBERs. The panel classified it as DLBCL with
plasmablastic features because of EBV negativity that
excludes DLBCL-E and strong expression of PAX5, a
feature inconsistent with a diagnosis of plasmablastic
lymphoma, as stated in the WHO classification.
PTLD
This category included five cases, which were classified as
polymorphic (one) and monomorphic (four). The case
presented by F. Facchetti was a 46-year-old male, who
developed a polymorphic PTLD 20 years following renal
transplantation. The patient presented with fever, diffuse
lymphadenopathy, lung nodules, and pleural and pericardial
effusions. Microscopic examination showed scattered large
cells with HRS-like morphology that revealed strong CD20
positivity, variable CD30 expression, and negativity for
both CD15 and CD138, in a background of numerous
reactive T lymphocytes. The blastic elements were EBV
positive (EBERs ISH
+, LMP1
+, and EBNA2
partly+). The
process had features intermediate between THRLBCL and
CHL: similar cases, nowadays included among poly-
morphic PTLD, have in the past possibly been referred to
as “Hodgkin-like” PTLD [1]. Notably, the administration of
Foscarnet produced a dramatic improvement of the clinical
conditions with reduction of EBV viremia from 26,100 to
1,500 after 1 week of treatment. The diagnosis of CHL-type
PTLD was excluded because of the strong and homogeneous
expression of CD20 with variable positivity for CD30,
CD15
−, and EBNA2
+ and response to antiviral treatment.
Of the monomorphic cases, two were EBV
+ and two
EBV
−. EBV
+ monomorphic PTLD usually have a late GC/
post-GC phenotype (CD10
−, BCL6
±,I R F 4 / M U M 1
+,
CD138
variably+), while the EBV
− ones are more likely to
have a GC-type phenotype (CD10
±, BCL6
+, IRF4/MUM1
−,
CD138
−). However, all four cases revealed a post-GC
profile. The first of these cases—presented by N. Rooney
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underwent kidney transplantation. The patient developed
bleeding per rectum caused by multiple ulcers in the colon
in the absence of previous inflammatory bowel disease.
PTLD with DLBCL morphology was diagnosed on a colon
biopsy. Despite the reduction of tacrolimus and the
administration of rituximab, the patient’s general conditions
worsened and a subtotal colectomy was required. Interest-
ingly, rituximab had almost abolished CD20 expression
when compared to the endoscopic biopsy but had no impact
on the lymphoid cells that maintained their EBV positivity
and high Ki-67 reactivity. Notably, different clonal IGVH@
rearrangements were detected in three different blocks from
the large bowel. The other EBV
+ monomorphic PTLD
presented in the graft of a 17-year-old male who—1 year
prior—had undergone kidney transplantation for end-stage
renal disease secondary to reflux nephropathy. It was
diagnosed by the contributors and panelists as monomor-
phic PTLD, DLBCL type with HL-like features. This
interpretation is consistent with the statement that “in
monomorphic PTLD, some cells may be bizarre and even
multinucleated and even resemble RS-like cells” [1]. The
phenotype also supported this interpretation (CD79a
+,
CD20
+/−, PAX5
+strong, CD138
+, IRF4/MUM1
+, CD30
−/+,
and CD15
−). Notably, endothelial cells were affected by
CMV infection. Of the two EBV-PTLD, one occurred in
the stomach of a 58-year-old male who had received a
kidney transplant 22 years previously. The interest of this
case resided in the phenotypic characteristics of the
neoplastic cells that morphologically fulfilled the criteria
for the diagnosis of DLBCL. In particular, they showed
negativity for B cell markers (CD20, CD79a, CD138, and
PAX5) but carried mature B cell clonality genotype. The
last case, also EBV negative, occurred in a female 10 years
after a heart transplant performed when aged one for
Kawasaki disease. She developed multiple polypoid masses
in the terminal ileum with intussusceptions that led to
partial small-bowel resection. In spite of CHOP chemo-
therapy that turned out totally ineffective, the tumor
relapsed several times in the bowel and lung. Microscop-
ically, it showed immunoblastic morphology with plasma-
blastic features. This was supported by the molecular
profile that showed CD45
−/+,C D 2 0
+variable,C D 7 9 a
+,
PAX5
−, IRF4/MUM1
+, BLIMP1
+/−, CD56
−, IgA/k
+, and
LANA
−. IGVH@ genes were clonally rearranged.
LYG and related conditions
This group of cases was to some extent related to the
previous and following categories. LYG is an angiocentric
and angiodestructive lymphoproliferative disease involving
extranodal sites, composed of EBV
+ B cells admixed with
reactive T lymphocytes, which usually predominate. The
lesion has a spectrum of histological grades and clinical
aggressiveness, which is related to the proportion of large B
cells. Three of the submitted cases fulfilled such criteria.
They occurred in patients in the adult life (aged 34, 37, and
39, respectively) with a male/female ratio of 2:1. Morpho-
logically, all cases were grade 3 and showed angiocentricity
and angioinvasiveness by large B cells (CD20
+, CD30
+,
LMP1
+, EBERs
+) that caused extensive necrosis and were
admixed with variable amounts of reactive T lymphocytes.
When performed, molecular analysis revealed clonal
IGVH@ gene rearrangement. Interestingly, one case—
submitted by G. Rassidakis (Fig. 7a–d)—occurred in the
skin in the recipient of a kidney transplant. Solid organ
transplantation is regarded as one of the LYG predisposing
conditions along with Wiskott-Aldrich syndrome, HIV
infection, and X-linked lymphoproliferative syndrome [1].
The other two cases showed lung involvement, as com-
monly seen in LYG and originally described by Liebow et
al. [87]. In one of them, the disease also affected lymph
nodes,afindingthatisrareinthissetting[1]. Finally, the third
case was recorded in a patient with a history of Wegener
granulomatosis (WG) that lasted 10 months and had been
treated with methotrexate, i.e., an immunosuppressive agent
implicated in the development of lymphoproliferative dis-
orders [1]. Although originally described as a variant of WG
[87], LYG does represent a distinct disease and so far no
transformation of WG into LYG has been reported in the
literature. Thus, in the absence of any morphological
evidence, it remains a matter of speculation whether or not
the original clinical diagnosis of WG was correct.
The last case included in this group shared the age
(36 years), disease spread, and morphological features with
the other cases described above. However, it turned out to
be EBV negative, contradicting one of the criteria for the
diagnosis of LYG. Therefore, the case was diagnosed as
angiocentric DLBCL, HHV8 negative by the panel. A
literature search revealed only one similar case in a patient
with a 3-year-history of methotrexate treatment for rheu-
matoid arthritis [88].
EBV
+ lymphoproliferative disorders in the course
of immunosuppressive hematological malignancies
Three cases were included in this group, which corre-
sponded to EBV-driven lymphoproliferative disorders. The
underlying hematological diseases were represented by NK
cell large granular lymphocyte disorder (LGL), refractory
anemia with excess of blast (RAEB)-2, and chronic
lymphocytic leukemia (CLL), respectively. The latter
occurred in a 76-year-old male who had been treated with
fludarabine, a drug which is well known for its immuno-
suppressive action [89, 90], as well as for the risk of
inducing EBV
+ lymphoproliferative disorders in patients
230 J Hematopathol (2009) 2:211–236treated for indolent B cell lymphomas [91]. In this case, it
remained unsettled whether or not the abdominal large B
cell tumor (expressing CD20, CD79a, CD30 (partly),
BCL2, and LMP-1) was clonally related to the underlying
CLL (CD20
+, CD79a
+, CD5
+, CD23
−, EBV
−), since the
only molecular analysis performed consisted in EBERs
ISH. In particular, a review of the literature showed that an
EBV
+ large B cell component (so-called Richter’s syn-
drome) may develop within the CLL setting as either
transformation of the existing tumor or a de novo process
[92–95]. The focal positivity of large B cells for CD5
slightly favored a clonal relationship. The patient with LGL
was a 79-year-old female who did not receive any therapy
for her disorder. Suddenly, she developed a skin lesion on
her right leg, composed of large cells with plasmablastic
features that were CD20
+ (in part), CD79a
+, CD30
+ (a
few), CD138
+ (most), and Ki-67
+ (70%). FISH displayed
BCL2 and BCL6 abnormal translocation patterns as well as
p53 gene deletion. The panel diagnosed this case—
submitted by M Twohig (Fig. 7e–h)—as EBV
+ lympho-
Fig. 7 a–d Session 4, case 24:
LYG grade 3. The neoplastic
growth shows angiocentricity
and angioinvasiveness (a). At
immunohistochemistry, lympho-
matous cells express CD20 (b)
and partly CD30 (b, inset) and
are admixed with abundant
CD3
+ T lymphocytes (c). ISH
reveals EBV integration
(arrowed; d). e–h Session 4,
case 16: EBV
+ LPD mimicking
DLBCL, leg type. The tumor
infiltrates the deep dermis and
subcutaneous tissue (e) and
consists of large cells with plas-
mablastic features (f) that dis-
play high Ki-67 rate (g) and
EBV integration at ISH (h). i–
l Session 4, case 23: DLBCL
associated with chronic inflam-
mation (PAL). The lymphoma-
tous population, showing
immunoblastic/plasmablastic
features (i), expresses CD20 (j),
CD79a (k), and EBNA2 (l). m–
p Session 4, case 32: HHV6
+
THRLBCL. Scattered neoplastic
cells (m) are comprised within a
reactive population consisting of
small lymphocytes and histio-
cytes (m). At immunohisto-
chemistry, they express CD20
(n), are surrounded by CD3
+ T
lymphocytes (n, inset) and turn
positive for the virus-associated
antigen HIND (o). Electron mi-
croscopy shows viral particles
consistent with HHV6 (p)
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Finally, the third case occurred in a 59-year-old male with
RAEB-2 and high EBV IgG and IgA titers that developed
generalized lymphadenopathy. A laterocervical lymph node
biopsy was consistent with THRLBCL. The neoplastic cells
(CD20
+, CD79a
+/−, BCL6
−, IRF4/MUM1
+,C D 3 0
+/−,
EBERs
+, LMP-1
+/−, and CD15
−) were embedded within a
reactive T cell component. PCR revealed an IGVH@ gene
monoclonal band in a strong polyclonal background. Since
RAEB-2 had apparently remained untreated, the panel
presumed that the myelodysplastic syndrome was sufficient
to cause immunosuppression, as LGL in the previous case.
Therefore, a final diagnosis of immunodeficiency-related
lymphoproliferative disorder was made. The disease had a
fatal outcome, since various courses of chemotherapy with
rituximab remained ineffective.
Chronic inflammation-associated DLBCL
In the WHO classification, DLBCL associated with chronic
inflammation is a subtype of DLBCL occurring in the
context of long-standing chronic inflammation and showing
association with EBV. Most cases involve body cavities or
narrow spaces. Pyothorax-associated lymphoma (PAL) is a
prototypic form and develops in the pleural cavity of
patients with long-standing pyothorax. Other settings of
long-standing chronic suppuration/inflammation, which can
favor the onset of the tumor, are chronic osteomyelitis,
metallic implant, or chronic skin ulcer. There is probably a
role for chronic inflammation at the local site in the
proliferation of EBV-transformed B cells by enabling them
to escape from the host immune surveillance (through IL-
10, IL-6, and IL-6 receptor). Although most cases have
been recorded in Japan, DLBCL associated with chronic
inflammation can be encountered also in Western Countries
[96, 97]. A typical example of PAL was presented by P.
Gaulard (Fig. 7i–l). It occurred in a 69-year-old male who
had undergone artificial pneumothorax 35 years prior. The
tumor presented as a huge mass that involved the anterior
chest wall and was associated with weight loss and pleural
effusion. It consisted of immunoblasts with features of
plasmablastic/plasmacellular differentiation, frequent apo-
ptotic bodies, and numerous mitotic figures. These
expressed CD20, CD79a, CD138, CD30 (heterogeneously),
and IRF4/MUM1. They were monotypic kappa with
immunohistochemistry and monoclonal by PCR. Typically,
they were EBERs
+ and expressed latency III pattern as
found in about 60% of PAL cases.
Other virus-associated lymphoproliferations
This group included the instructive case from a 21-year-old
female who had undergone right tonsillectomy when she
was 6 years old. She presented with malaise of several
weeks duration, bilateral cervical lymphadenopathy, hepa-
tomegaly, atypical lymphocytosis in the peripheral blood
(7.6×10
9/L), and left necrotising tonsillitis, refractory to
antibiotics and dexamethazone. Monospot was positive, as
was serology for EBV IgG and IgM. A left tonsillectomy
was performed for air obstruction. Monospot was positive,
as was serology for EBV IgG and IgM. Morphologically,
there was a diffuse effacement of the normal tonsil structure
due to a lymphoid population with blastic morphology and
high mitotic index that expressed CD20, CD79a, IRF4/
MUM1, EBERs, LMP-1, CD30 (in part), and CD45 and
was negative for CD10, BCL6, CD138, ALK1, and HHV8.
Ig light chains revealed a polytypic pattern. Admixed with
the blasts were numerous cytotoxic T lymphocytes (CD3
+,
CD8>CD4, and granzyme B
+). The patient recovered
2 months later. This case was diagnosed by both the
contributors and panel as large B cell proliferation in acute
EBV infection (infectious mononucleosis). This case under-
lines the risk of misinterpreting such pattern as DLBCL, if
the clinical and laboratory data are unknown and a limited
panel of reagents is applied [98–101]. Another remarkable
case—submitted by P. Adam (Fig. 7m–p)—was a 74-year-
old male who underwent a laterocervical lymph node
biopsy. The morphologic and immunohistochemical find-
ings were consistent with THRLBCL. However, viral
inclusion bodies were seen both in the tumor cells and
reactive elements. Antibodies against early and late anti-
gens as well as electron microscopy showed that such
inclusions corresponded to HHV6 infection. This case
expands the spectrum of herpesvirus infections associated
with malignant lymphomas. HHV6 has been associated
only with angioimmunoblastic T cell lymphoma [102, 103].
There is, however, no clear evidence for a causative role.
Conclusions
The workshop jointly organized by the EAHP and the SH
in 2008 in Bordeaux focused on the difficult topic of gray-
zone lymphomas. In the 2008 WHO classification, these
borderline categories were added mainly to delineate the
borderlands between BL and DLBCL and DLBCL and HL.
As emerged from the discussions during the workshop—
among the panel members, the auditorium, and the authors
of the WHO classification—several issues were considered
important for the proper use of these borderline categories.
The main two issues were that all information—cytomor-
phologic, biologic, and clinical—should be considered to
arrive at an accurate diagnosis, and second, whenever
possible, distinct entities should be diagnosed. It was
agreed, however, that this was not possible in all cases,
thus justifying the creation of borderline diagnoses (unclas-
232 J Hematopathol (2009) 2:211–236sifiable), looked upon as practical categories awaiting for
more data to become available and not as discrete entities.
Session 1 was devoted to the possible overlap between
BL and DLBCL. Specifically, this overlap is caused by
similarities in morphology, phenotype, and genetic aberra-
tions. During the session, it became clear that the “double-
hit” cases (a combination of a MYC breakpoint with mostly
BCL2 breakpoints and other recurrent chromosomal break-
points), often with distinct morphological features of BL
should fall in a novel category of “B cell lymphoma,
unclassifiable, with features intermediate between DLBCL
and BL.” In fact, there was some discussion whether or not
B cell lymphomas, irrespective of morphology, should be
moved to this novel category, but at the end it was felt that
this change would be premature. The second most difficult
category that remains in the gray zone consists of
lymphomas with morphological features of both DLBCL
and BL, but with a phenotype that is consistent with BL, in
particular since up to 40% of such cases may have a MYC
breakpoint. Many of such cases might fall in this novel
category; however, it was felt that cases with a typical
morphology of DLBCL should be kept in the DLBCL
category, in spite of the fact that DLBCL patients with a
MYC breakpoint will have a relatively poor prognosis.
Session 2 was devoted to mediastinal gray-zone lym-
phoma and other lymphomas with atypical immunopheno-
type that caused differential diagnostic problems, often
between CHL and NHL. During the discussion, it was
stressed that deviation of a single marker or criterion, e.g.,
strong and uniform CD20 expression in otherwise typical
HL, was not sufficient for placing a case in the category of
“B cell lymphoma, unclassifiable, with features intermedi-
ate between DLBCL and CHL,” but that a hybrid
phenotype not being in line with current morphologic and/
or biologic concepts would well be. Examples of those
features could be a significant mononuclear large B cell
component not compatible with HL or uniformly strong
expression of pan B cell markers along with the expression
of one or more of the transcription factors BOB.1, OCT2,
and PU.1 in a mediastinal tumor with morphological
features of CHL. This stresses the need of doing a complete
phenotype (B cell markers and transcription markers) in
cases with morphological features of CHL with strong and
uniform CD20 expression.
Among the tumors with unusual phenotypes presented
during this session were DLBCL with cyclin D1 over-
expression and cases with aberrant expression of T-cell-
associated markers. Also, in this group, several cases of T
cell lymphomas with CD30 and/or CD15 expression
including ALCL cases were shown.
Session 3 dealt with the differential diagnosis between
NLPHL and THRLBCL, and the gray zones between CHL
and DLBCL, mainly THRLBCL in lymph nodes. The main
issue addressed during the workshop was to define criteria
to reliably distinguish these entities. Within the first topic, it
was considered important that NLPHL can manifest in
various progression stages, being characterized by diffuse
areas and by progressive loss of the typical small B cell
background. While it was agreed that transition of NLPHL
into THRLBCL might exist, the proposal of the WHO
classification to name areas reminiscent of THRLBCL in an
otherwise typical NLPHL background “THRLBCL-like
areas” was generally considered a practical guideline. It
implies that one single nodule of typical NLPHL in a
THRLBCL background is sufficient to exclude de novo
THRLBCL. Other important issues highlighted during the
workshop were the reactivity of the LP cells for IgD in the
progressed cases or the rare expression of CD15. In
addition, three bona fide NLPHL showed the presence of
EBV genomes in their nuclei, a feature considered unusual
for NLPHL and rather characteristic of CHL.
Several cases submitted to the workshop exemplified the
difficulties in accurately separating cases of CHL from
THRLBCL due to overlapping clinical, morphological,
and/or immunophenotypic features. In general, CHL is
negative or weakly positive for B cell antigens and PAX5
and does show loss of transcription factors expression;
however, deceptively similar cases may be placed in the
THRLBCL category, when CD15 and/or CD30 are nega-
tive and CD20 and/or CD79a are strongly and uniformly
positive. Similar to the mediastinal gray zone, cases with
CHL and DLBCL boundary features also exist in lymph
nodes. The cases presented during the workshop showed an
amazing variety and overlapping immunohistochemical
features, thus giving clear evidence for the need of a
borderline category. In addition, the frequent association of
these cases with EBV also discloses overlapping features
with (THRBCL-like) EBV-associated DLBCL of the
elderly in young patients.
Session 4 dealt with the heterogeneous lymphoma
categories of EBV-positive lymphomas, lymphomas occur-
ring in HIV
+ individuals, and PTLD-related B cell
lymphoproliferations. This session exemplify how meticu-
lous diagnostic assessment of the cases is needed in arriving
at the correct diagnosis. Clinical background information,
and the exact knowledge of the sites involved, is absolutely
essential in providing a correct diagnosis. EBV-associated
lymphoproliferations such as posttransplant lymphoproli-
ferative disorders, body-cavitary-based or extracavitary
PEL or HIV-associated or lymphoproliferations following
iatrogenic measurements cannot be diagnosed without
proper clinical information. On the other hand, on purely
morphological grounds, these cases might have been put
into a different category. With respect to EBV association,
the positivity of a DLBCL for CD30 should encourage
performing EBER ISH or LMP-1 immunohistochemistry.
J Hematopathol (2009) 2:211–236 233In the workshop, EBV
+ DLBCL-E showed regular
CD79a expression and frequent CD20 positivity, usually
with strong PAX5, BOB.1, and OCT-2 staining, thus setting
it apart from EBV-associated CHL. Among lymphomas
occurring in HIV
+ individuals, plasmablastic lymphomas
and BL were the two categories represented. Two cases
were consistent with the diagnosis of extracavitary PEL
and, most interestingly, were diagnosed in immunocompe-
tent hosts, a finding rarely encountered in elderly individ-
uals from areas with high prevalence for HHV8 infection
like the Mediterranean. In keeping with what has been
stated above, the PTLD cases referred to the workshop
often presented with hybrid morphological and immuno-
phenotypic features intermediate between CHL and
DLBCL; since two of the PTLD monomorphic DLBCL
were EBV negative, clinical information is essential in
arriving at the correct diagnosis.
Examples of lymphomatoid granulomatosis, EBV-
associated lymphoproliferative disorders in the course of
immunosuppressive hematological malignancies, cases of
DLBCL associated with chronic inflammation, and other
virus-associated lymphoproliferations completed the spec-
trum of diseases seen in session 4. For the latter category,
two instructive cases were presented, both with an initial
suspicion of malignant lymphoma but turning out to
represent virus-associated reactive lymphoproliferations,
one associated with EBV and one with HHV6. These
difficult cases again underline the risk of misinterpreting
such reactive disorders as DLBCL, if the clinical and
laboratory data are unknown and/or a limited panel of
antibodies is applied.
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